Breaking News Instant updates and real-time market news.

PANW

Palo Alto Networks

$161.06

-0.29 (-0.18%)

07:11
11/22/16
11/22
07:11
11/22/16
07:11

Oppenheimer remains confident in Palo Alto Networks leadership position

Oppenheimer analyst Shaul Eyal says that while Palo Alto Networks' mixed results were "somewhat disappointing", he remains confident in its leadership position and ability to expand its platform. The analyst is "not losing sight of overall opportunity" as the company morphs into a platform provider and says the dip could provide an attractive buying opportunity. He reiterates an Outperform rating and $184 price target on the shares.

  • 08

    Dec

  • 08

    Dec

PANW Palo Alto Networks
$161.06

-0.29 (-0.18%)

10/18/16
BERN
10/18/16
NO CHANGE
BERN
Palo Alto Networks growth outlook positive, says Bernstein
After analyzing Palo Alto's results, Bernstein analyst Pierre Ferragu raised his 2020 revenue estimate for the company by about 20%. The analyst says that the company's installed base is growing very quickly, resulting in a slowdown in its product revenue growth. However, he expects the company's billings growth to be very strong "for multiple years," and he keeps an Outperform rating on the shares.
11/17/16
PIPR
11/17/16
NO CHANGE
Target $184
PIPR
Overweight
Piper recommends buying Palo Alto into earnings
Piper Jaffray analyst Andrew Nowinski says his firm's recent channel checks indicate Palo Alto Networks' demand trends have improved since last quarter. The setup heading into the earnings call is better than it has been over the last 12 months amid "ramping" demand trends, lowered expectations and the now complete accounting changes, Nowinski tells investors in a pre-earnings research note. He raised his price target for the shares to $184 from $170 and reiterates an Overweight rating on Palo Alto.
11/17/16
OPCO
11/17/16
NO CHANGE
Target $184
OPCO
Outperform
Palo Alto Networks price target raised to $184 from $177 at Oppenheimer
Oppenheimer analyst Shaul Eyal raised his price target for Palo Alto Networks to $184 from $177, saying trends are becoming more predictable and the company's Q1 set up is attractive. The analyst remains confident in Palo Alto Networks' consistent product execution and momentum in SaaS-based subscription services. He reiterates an Outperform rating on the shares.
11/22/16
UBSW
11/22/16
NO CHANGE
Target $160
UBSW
Buy
Palo Alto Networks missed but conviction remains, says UBS
UBS analyst Brent Thill noted Palo Alto Networks missed Q1 estimates and that investors are likely to be skeptical about the company's prospects, especially with lighter Q2 guidance. Thill said he is sticking with the name as management has conviction there will be an acceleration in the second half of the year. Thill maintained his Buy rating and lowered his price target to $160 from $165 on Palo Alto Networks shares.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$10.80

0.25 (2.37%)

16:01
12/04/16
12/04
16:01
12/04/16
16:01
Hot Stocks
Aduro Biotech reports presentation of BION-1301 data »

Aduro Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

15:59
12/04/16
12/04
15:59
12/04/16
15:59
Hot Stocks
Trillium Therapeutics reports presentation of TTI-621 data »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLUE

bluebird bio

$69.75

1.1 (1.60%)

15:47
12/04/16
12/04
15:47
12/04/16
15:47
Hot Stocks
bluebird bio reports new data from HGB-205 study of LentiGlobin »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

15:43
12/04/16
12/04
15:43
12/04/16
15:43
Hot Stocks
Bellicum Pharmaceuticals reports updated data from BPX-501 study »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

15:39
12/04/16
12/04
15:39
12/04/16
15:39
Hot Stocks
Alnylam reports Phase 1 givosiran data, says plans Phase 3 study late 2017 »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$31.63

0.17 (0.54%)

, ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

15:32
12/04/16
12/04
15:32
12/04/16
15:32
Hot Stocks
Spark Therapeutics, Pfizer report updated preliminary data on SPK-9001 »

Spark Therapeutics (ONCE)…

PFE

Pfizer

$31.63

0.17 (0.54%)

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

15:26
12/04/16
12/04
15:26
12/04/16
15:26
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.